Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...
This was the stock's fourth consecutive day of gains.
This was the stock's third consecutive day of gains.
5don MSN
Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...
CNBC’s Jim Cramer delivers his daily Mad Dash. Drones Banned in New Jersey Over 'Imminent Security Threat' Finnair New A350 - ...
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third ...
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 ...
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s ...
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $408.18, denoting a +0.72% change from the preceding trading day.
We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback